Diabetes TrialNet is an international clinical trial network aimed to delay or prevent the onset of type 1 diabetes. As described, the new Diabetes TrialNet structure will now include a Diabetes TrialNet Clinical Hub, the Director of which will be part of the TrialNet leadership team including representatives of the NIH, the TrialNet Coordinating Center, and TrialNet chairman. The Benaroya Research Institute (BRI) serves as a nexus of T1D research, and with decades of clinical trial experience in T1D prediction and prevention, Dr. Greenbaum is uniquely qualified to serve as the TrialNet Clinical Network Hub (HUB). This application describes our proposal to become the Diabetes TrialNet Clinical HUB. We focus on three areas;activities to (a) enhance risk screening and prevention trial recruitment, (b) support clinical trials, and (c) enhance clinical administration and include proposed pilot studies to test innovative ideas for increasing recruitment, retention, and cost efficiencies.
Diabetes TrialNet is an international clinical trial network aimed to delay or prevent the onset of type 1 diabetes. This is an application from Dr. Greenbaum and the Benaroya Research Institute to become the Diabetes TrialNet Clinical Hub whose activities are designed to facilitate achieving this aim. The Director of the Diabetes TrialNet Clinical Hub will be part of the TrialNet leadership team including representatives of the NIH, the TrialNet Coordinating Center, and TrialNet chairman.
|Vecchio, Federica; Lo Buono, Nicola; Stabilini, Angela et al. (2018) Abnormal neutrophil signature in the blood and pancreas of presymptomatic and symptomatic type 1 diabetes. JCI Insight 3:|
|Redondo, Maria J; Steck, Andrea K; Sosenko, Jay et al. (2018) Transcription Factor 7-Like 2 (TCF7L2) Gene Polymorphism and Progression From Single to Multiple Autoantibody Positivity in Individuals at Risk for Type 1 Diabetes. Diabetes Care 41:2480-2486|
|Sanda, Srinath; Type 1 Diabetes TrialNet Study Group (2018) Increasing ICA512 autoantibody titers predict development of abnormal oral glucose tolerance tests. Pediatr Diabetes 19:271-276|
|Yeo, Lorraine; Woodwyk, Alyssa; Sood, Sanjana et al. (2018) Autoreactive T effector memory differentiation mirrors ? cell function in type 1 diabetes. J Clin Invest 128:3460-3474|
|Redondo, Maria J; Geyer, Susan; Steck, Andrea K et al. (2018) A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk. Diabetes Care 41:1887-1894|
|Greenbaum, Carla J; Speake, Cate; Krischer, Jeffrey et al. (2018) Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes-The TrialNet Experience. Diabetes 67:1216-1225|
|Haller, Michael J; Schatz, Desmond A; Skyler, Jay S et al. (2018) Low-Dose Anti-Thymocyte Globulin (ATG) Preserves ?-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes. Diabetes Care 41:1917-1925|
|Redondo, Maria J; Geyer, Susan; Steck, Andrea K et al. (2018) TCF7L2 Genetic Variants Contribute to Phenotypic Heterogeneity of Type 1 Diabetes. Diabetes Care 41:311-317|
|Sosenko, Jay M; Geyer, Susan; Skyler, Jay S et al. (2018) The influence of body mass index and age on C-peptide at the diagnosis of type 1 diabetes in children who participated in the diabetes prevention trial-type 1. Pediatr Diabetes 19:403-409|
|Hao, Wei; Woodwyk, Alyssa; Beam, Craig et al. (2017) Assessment of ? Cell Mass and Function by AIRmax and Intravenous Glucose in High-Risk Subjects for Type 1 Diabetes. J Clin Endocrinol Metab 102:4428-4434|
Showing the most recent 10 out of 16 publications